59 products were found matching "K08726"!

Antibody in PBS with 0.02% sodium azide, 50% glycerol and 0.4-0.5mg/ml BSA. Epoxide hydrolase 2 is a bifunctional enzyme. The C-terminal domain has epoxide hydrolase activity and acts on epoxides (alkene oxides, oxiranes) and arene oxides. It also plays a role in xenobiotic metabolism by degrading potentially toxic...

BI-1935 is an inhibitor of soluble epoxide hydrolase (sEH, IC50 = 7 nM). It is selective for sEH over the cytochrome P450 (CYP) isoforms CYP2J2, CYP2C9, and CYP2C19 (IC50s = >1,000 nM for all). See the Structural Genomics Consortium (SGC) website for more information. Formal Name:...

EpETrE metabolites of arachidonic acid such as 11(12-EpETrE and 14(15)-EpETrE have been identified as endothelium derived hyperpolarizing factors with vasodilator activity. Soluble epoxide hydrolase (sEH) catalyzes the conversion of EpETrEs to the corresponding DiHETrEs thereby diminishing their activity. Inhibitors...

Soluble epoxide hydrolase (sEH) converts epoxides to their corresponding diols. Inhibitors of sEH have anti-inflammatory, anti-hypertensive, neuroprotective, and cardioprotective effects. TPPU is a potent inhibitor of both human and mouse sEH (IC50 = 3.7 and 2.8 nM, respectively). The pharmacokinetics of this...

Soluble epoxide hydrolase (sEH) inhibitors have important therapeutic use by increasing the in vivo concentration of EETs and other fatty acid epoxides, resulting in anti-inflammatory, antihypertensive, neuroprotective, and cardioprotective effects. CAY10640 is a 1-aryl-3-(1-acylpiperidin-4-yl)urea analog that...

Soluble epoxide hydrolase (sEH) is a member of the alpha/beta-hydrolase fold enzyme family that catalyzes the hydrolysis of bioactive fatty acid epoxides to inactive vicinal diols. It is a homodimer in which each subunit is composed of two domains, a C-terminal epoxide hydrolase domain and an N-terminal phosphatase...

Epoxyeicosatrienoic acid (EpETrE, EET) metabolites of arachidonic acid such as 11(12)-EET and 14(15)-EET have been identified as endothelium derived hyperpolarizing factors with vasodilator activity. Soluble epoxide hydrolase (sEH) catalyzes the conversion of EETs to the corresponding dihydroxy eicosatrienoic acids...

CDU is an inhibitor of soluble epoxide hydrolase (sEH, IC50s = 9. and 85. nM for the mouse and human enzymes, respectively). It inhibits the proliferation of, and decreases the levels of cyclin D1 in, primary human vascular smooth muscle cells (VSMCs) when used at a concentration of 10 µM. CDU (10 µM) induces...

Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)13(14)-EpDPA is a docosahexaenoic acid (DHA, Cay-90310) epoxygenase metabolite, derived via epoxidation of the 13,14-double bond of DHA. It has been detected in rat brain and spinal cord and is a preferred...

Docosahexaenoic acid (DHA, Cay-90310) is the most abundant omega-3 fatty acid in neural tissues, especially in the brain and retina. (±)7(8)-EpDPA is an epoxide derivative of DHA that is generated by the action of cytochrome P450 epoxygenases. It is naturally occurring in plasma and brain and spinal cord tissues and...

Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)10(11)-EpDPA is a docosahexaenoic acid (DHA, Cay-90310) epoxygenase metabolite, derived via epoxidation of the 10,11-double bond of DHA. It has been detected in rat brain and spinal cord, as well as human...

Soluble epoxide hydrolase (sEH) converts epoxides to their corresponding diols. Inhibitors of sEH have anti-inflammatory, anti-hypertensive, neuroprotective, and cardioprotective effects. trans-AUCB is a very potent inhibitor of sEH (IC50 = 0.5 nM). It displays high oral bioavailability for doses ranging from 0.01...